Earnings Feed
Start Free
Home/Filings/4/0001273013-08-000075
4//SEC Filing

PHARMACOPEIA INC 4

Accession 0001273013-08-000075

CIK 0001273013operating
View on SEC.govCompany Profile

Filed

Dec 23, 7:00 PM ET

Accepted

Dec 24, 10:52 AM ET

Size

41.0 KB

Accession

0001273013-08-000075

Insider Transaction Report

Form 4
Period: 2008-12-23
PHARMACOPEIA INCPCOP
WEBB MARIA L
VP, Drug Discovery Research
Transactions
  • Disposition to Issuer

    Common Stock

    2008-12-23−17,700.83→ 0 total
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2008-12-23$0.20/sh−8,355$1,671→ 0 total
    Exercise: $5.85From: 1999-07-30Exp: 2008-07-30→ Common Stock (8,355 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2008-12-23$0.20/sh−11,435$2,287→ 0 total
    Exercise: $19.77From: 2001-07-11Exp: 2010-07-11→ Common Stock (11,435 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2008-12-23$0.20/sh−20,000$4,000→ 0 total
    Exercise: $3.84From: 2009-02-25Exp: 2018-02-25→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2008-12-23$0.20/sh−21,311$4,262→ 0 total
    Exercise: $5.05From: 2003-05-08Exp: 2012-05-08→ Common Stock (21,311 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2008-12-23$0.20/sh−8,364$1,673→ 0 total
    Exercise: $19.77From: 2001-07-11Exp: 2010-07-11→ Common Stock (8,364 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2008-12-23$0.20/sh−4,103$821→ 0 total
    Exercise: $4.75Exp: 2016-03-01→ Common Stock (4,103 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2008-12-23$0.20/sh−11,688$2,338→ 0 total
    Exercise: $5.05From: 2003-05-08Exp: 2012-05-08→ Common Stock (11,688 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2008-12-23$0.20/sh−20,897$4,179→ 0 total
    Exercise: $4.75Exp: 2016-03-01→ Common Stock (20,897 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2008-12-23$0.20/sh−14,271$2,854→ 0 total
    Exercise: $5.30From: 2002-09-24Exp: 2011-09-24→ Common Stock (14,271 underlying)
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2008-12-23$0.20/sh−13,530$2,706→ 0 total
    Exercise: $8.88From: 2005-03-16Exp: 2014-03-16→ Common Stock (13,530 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2008-12-23$0.20/sh−4,021$804→ 0 total
    Exercise: $5.85From: 1999-07-30Exp: 2008-07-30→ Common Stock (4,021 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2008-12-23$0.20/sh−13,970$2,794→ 0 total
    Exercise: $8.88From: 2005-03-16Exp: 2014-03-16→ Common Stock (13,970 underlying)
  • Tax Payment

    Common Stock

    2008-12-23−3,534→ 17,700.83 total
  • Disposition to Issuer

    Incentive Stock Option (right to buy)

    2008-12-23$0.20/sh−18,609$3,722→ 0 total
    Exercise: $4.04From: 2000-05-28Exp: 2009-05-28→ Common Stock (18,609 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2008-12-23$0.20/sh−12,190$2,438→ 0 total
    Exercise: $4.04From: 2000-05-28Exp: 2009-05-28→ Common Stock (12,190 underlying)
  • Disposition to Issuer

    Non-Qualified Stock Option (right to buy)

    2008-12-23$0.20/sh−18,728$3,746→ 0 total
    Exercise: $5.30From: 2002-09-24Exp: 2011-09-24→ Common Stock (18,728 underlying)
Footnotes (3)
  • [F1]Disposed of in connection with tax withholding obligation of the reporting person upon the vesting of 12,000 restricted stock units as a result of the consummation of the transactions contemplated by a merger agreement (the "merger agreement") by and among Pharmacopeia, Inc. ("Pharmacopeia"), Ligand Pharmaceuticals Incorporated ("Ligand"), Margaux Acquisition Corp., a wholly-owned subsidiary of Ligand, and Latour Acquisition, LLC, a wholly-owned subsidiary of Ligand.
  • [F2]Disposed of pursuant to the merger agreement in exchange for approximately 10,593.95 shares of Ligand common stock having a market value of $2.58 per share on the effective date of the merger and $5,487.26 in cash, without interest. In addition, the reporting person received one contingent value right ("CVR") for each share of the Pharmacopeia common stock disposed of in the merger by the reporting person. The CVRs provide each holder the right to receive approximately $0.50 per share if Ligand enters into a license, sale, development, marketing or option agreement with respect to any product candidate from Pharmacopeia's dual angiotensin and endothelin receptor antagonist program (other than any agreement with Bristol-Myers Squibb Company or any of its affiliates) on or prior to December 31, 2011.
  • [F3]This option was canceled in connection with Pharmacopeia's offer to purchase all outstanding options, whether vested or unvested, to purchase shares of Pharmacopeia common stock, par value $0.01 per share, which was consummated on December 23, 2008. The reporting person received a cash payment of $0.20 per share of common stock issuable upon exercise of each such option.

Documents

1 file

Issuer

PHARMACOPEIA INC

CIK 0001273013

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001273013

Filing Metadata

Form type
4
Filed
Dec 23, 7:00 PM ET
Accepted
Dec 24, 10:52 AM ET
Size
41.0 KB
View on SEC.gov